Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27128212,time to peak serum concentration [Tmax ],"Tofacitinib PK was characterized by rapid absorption (time to peak serum concentration [Tmax ] 0.5-1 hour), rapid elimination (mean terminal half-lives 2.3-3.1 hours), and dose-proportional systemic exposures (peak serum concentration [Cmax ] and area under the serum concentration-time curve from time zero to infinity [AUC0-∞ ]).","Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128212/),h,0.5-1,4641,DB08895,Tofacitinib
,27128212,terminal half-lives,"Tofacitinib PK was characterized by rapid absorption (time to peak serum concentration [Tmax ] 0.5-1 hour), rapid elimination (mean terminal half-lives 2.3-3.1 hours), and dose-proportional systemic exposures (peak serum concentration [Cmax ] and area under the serum concentration-time curve from time zero to infinity [AUC0-∞ ]).","Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128212/),h,2.3-3.1,4642,DB08895,Tofacitinib
,33433317,tmax,"tmax was ~ 0.6 hours later, and Cmax was ~ 27% lower after a high-fat diet in the fasted state.",Evaluation of tofacitinib citrate bioequivalence based on pharmacokinetic parameters in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33433317/),h,0.6,6689,DB08895,Tofacitinib
,24464803,total percentage of administered radioactive dose recovered,"Following administration of a single 50-mg (14)C-labeled tofacitinib dose to healthy male subjects, the mean (standard deviation) total percentage of administered radioactive dose recovered was 93.9% (±3.6), with 80.1% (±3.6) in the urine (28.8% parent), and 13.8% (±1.9) in feces (0.9% parent).","The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24464803/),%,93.9,12627,DB08895,Tofacitinib
,24464803,total percentage of administered radioactive dose recovered,"Following administration of a single 50-mg (14)C-labeled tofacitinib dose to healthy male subjects, the mean (standard deviation) total percentage of administered radioactive dose recovered was 93.9% (±3.6), with 80.1% (±3.6) in the urine (28.8% parent), and 13.8% (±1.9) in feces (0.9% parent).","The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24464803/),%,80.1,12628,DB08895,Tofacitinib
,24464803,total percentage of administered radioactive dose recovered,"Following administration of a single 50-mg (14)C-labeled tofacitinib dose to healthy male subjects, the mean (standard deviation) total percentage of administered radioactive dose recovered was 93.9% (±3.6), with 80.1% (±3.6) in the urine (28.8% parent), and 13.8% (±1.9) in feces (0.9% parent).","The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24464803/),%,13.8,12629,DB08895,Tofacitinib
,24464803,terminal phase half-life,The mean terminal phase half-life was approximately 3.2 hours for both parent drug and total radioactivity.,"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24464803/),h,3.2,12630,DB08895,Tofacitinib
,33513294,CL/F,"The PK was described by a 1-compartment model parameterized in terms of CL/F (26.3 L/hour [h]) and V/F (115.8 L), with first-order absorption (Ka ; 9.85 h-1 ) and lag time (0.236 h).",Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33513294/),[l] / [[h·h],26.3,15621,DB08895,Tofacitinib
,33513294,V/F,"The PK was described by a 1-compartment model parameterized in terms of CL/F (26.3 L/hour [h]) and V/F (115.8 L), with first-order absorption (Ka ; 9.85 h-1 ) and lag time (0.236 h).",Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33513294/),l,115.8,15622,DB08895,Tofacitinib
,33513294,first-order absorption (Ka,"The PK was described by a 1-compartment model parameterized in terms of CL/F (26.3 L/hour [h]) and V/F (115.8 L), with first-order absorption (Ka ; 9.85 h-1 ) and lag time (0.236 h).",Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33513294/),1/[h],9.85,15623,DB08895,Tofacitinib
,33513294,lag time,"The PK was described by a 1-compartment model parameterized in terms of CL/F (26.3 L/hour [h]) and V/F (115.8 L), with first-order absorption (Ka ; 9.85 h-1 ) and lag time (0.236 h).",Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33513294/),h,0.236,15624,DB08895,Tofacitinib
,33513294,elimination half-life,The derived elimination half-life was approximately 3.05 h.,Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33513294/),h,3.05,15625,DB08895,Tofacitinib
greater,34069798,concentration/apparent inhibition constant (Ki) ratios,"The concentration/apparent inhibition constant (Ki) ratios of voriconazole were greater than two, indicating that the inhibition of tofacitinib metabolism could be due to the inhibition of the CYP3A1/2 and CYP2C11 enzymes by voriconazole.",Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34069798/),,two,37380,DB08895,Tofacitinib
>,22233204,IC(50),"In vitro studies demonstrated low potential for CYP inhibition (IC(50) estimates tofacitinib > 30 µm), CYP3A4 mRNA induction (observed at tofacitinib concentrations ≥ 25 µm) and no effect on enzymatic activity of CYP substrates.","Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22233204/),µm,30,43868,DB08895,Tofacitinib
,31448433,50% of the maximum effect,"Model-estimated values of 50% of the maximum effect were 60.7 nM for upadacitinib and 119 nM for tofacitinib for IL-6-induced pSTAT3 inhibition, and 125 nM for upadacitinib and 79.1 nM for tofacitinib for IL-7-induced pSTAT5 inhibition.",Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31448433/),nM,60.7,44246,DB08895,Tofacitinib
,31448433,50% of the maximum effect,"Model-estimated values of 50% of the maximum effect were 60.7 nM for upadacitinib and 119 nM for tofacitinib for IL-6-induced pSTAT3 inhibition, and 125 nM for upadacitinib and 79.1 nM for tofacitinib for IL-7-induced pSTAT5 inhibition.",Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31448433/),nM,119,44247,DB08895,Tofacitinib
,31448433,50% of the maximum effect,"Model-estimated values of 50% of the maximum effect were 60.7 nM for upadacitinib and 119 nM for tofacitinib for IL-6-induced pSTAT3 inhibition, and 125 nM for upadacitinib and 79.1 nM for tofacitinib for IL-7-induced pSTAT5 inhibition.",Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31448433/),nM,125,44248,DB08895,Tofacitinib
,31448433,50% of the maximum effect,"Model-estimated values of 50% of the maximum effect were 60.7 nM for upadacitinib and 119 nM for tofacitinib for IL-6-induced pSTAT3 inhibition, and 125 nM for upadacitinib and 79.1 nM for tofacitinib for IL-7-induced pSTAT5 inhibition.",Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31448433/),nM,79.1,44249,DB08895,Tofacitinib
,31713350,maximum observed plasma concentration ratio,"Similarly, mean maximum observed plasma concentration ratio values were 99.5%, 118%, and 119%, respectively.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),%,99.5,58377,DB08895,Tofacitinib
,31713350,maximum observed plasma concentration ratio,"Similarly, mean maximum observed plasma concentration ratio values were 99.5%, 118%, and 119%, respectively.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),%,118,58378,DB08895,Tofacitinib
,31713350,maximum observed plasma concentration ratio,"Similarly, mean maximum observed plasma concentration ratio values were 99.5%, 118%, and 119%, respectively.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),%,119,58379,DB08895,Tofacitinib
,31713350,renal clearance,"Mean renal clearance was also similar, ranging across doses from 134 mL/min (5 mg) to 162 mL/min (1 mg) in Japanese volunteers, and 124 mL/min (30 mg) to 160 mL/min (1 mg) in Western volunteers.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),[ml] / [min],134,58380,DB08895,Tofacitinib
,31713350,renal clearance,"Mean renal clearance was also similar, ranging across doses from 134 mL/min (5 mg) to 162 mL/min (1 mg) in Japanese volunteers, and 124 mL/min (30 mg) to 160 mL/min (1 mg) in Western volunteers.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),[ml] / [min],162,58381,DB08895,Tofacitinib
,31713350,renal clearance,"Mean renal clearance was also similar, ranging across doses from 134 mL/min (5 mg) to 162 mL/min (1 mg) in Japanese volunteers, and 124 mL/min (30 mg) to 160 mL/min (1 mg) in Western volunteers.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),[ml] / [min],124,58382,DB08895,Tofacitinib
,31713350,renal clearance,"Mean renal clearance was also similar, ranging across doses from 134 mL/min (5 mg) to 162 mL/min (1 mg) in Japanese volunteers, and 124 mL/min (30 mg) to 160 mL/min (1 mg) in Western volunteers.","Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31713350/),[ml] / [min],160,58383,DB08895,Tofacitinib
,31284540,unabsorbed fraction,"Following oral administration of 10 mg/kg tofacitinib, the unabsorbed fraction from the rat intestine was 3.16% and the bioavailability (F) was 29.1%.",Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284540/),%,3.16,66622,DB08895,Tofacitinib
,31284540,bioavailability (F),"Following oral administration of 10 mg/kg tofacitinib, the unabsorbed fraction from the rat intestine was 3.16% and the bioavailability (F) was 29.1%.",Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31284540/),%,29.1,66623,DB08895,Tofacitinib
,30193392,flow rate,"The method employs liquid extraction of tofacitinib from DBS disk of mice whole blood followed by chromatographic separation using 5 mM ammonium acetate (pH 6.5):acetonitrile (20:80, v/v) at a flow rate of 0.60 mL/min on an X-Terra Phenyl column with a total run time 2.5 min.",Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC-ESI-MS/MS: Application to Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30193392/),[ml] / [min],0.60,71473,DB08895,Tofacitinib
,30193392,total run time,"The method employs liquid extraction of tofacitinib from DBS disk of mice whole blood followed by chromatographic separation using 5 mM ammonium acetate (pH 6.5):acetonitrile (20:80, v/v) at a flow rate of 0.60 mL/min on an X-Terra Phenyl column with a total run time 2.5 min.",Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC-ESI-MS/MS: Application to Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30193392/),min,2.5,71474,DB08895,Tofacitinib
,30193392,m/z,"The MS/MS ion transitions monitored were m/z 313→149 for tofacitinib and m/z 316→149 for the internal standard (13C3, 15N-tofacitinib).",Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC-ESI-MS/MS: Application to Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30193392/),,313,71475,DB08895,Tofacitinib
,30193392,m/z,"The MS/MS ion transitions monitored were m/z 313→149 for tofacitinib and m/z 316→149 for the internal standard (13C3, 15N-tofacitinib).",Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC-ESI-MS/MS: Application to Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30193392/),,149,71476,DB08895,Tofacitinib
,30193392,m/z,"The MS/MS ion transitions monitored were m/z 313→149 for tofacitinib and m/z 316→149 for the internal standard (13C3, 15N-tofacitinib).",Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC-ESI-MS/MS: Application to Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30193392/),,316,71477,DB08895,Tofacitinib
,24218541,maximal response (Cave50),"Projected efficacy could be predicted from total daily exposure irrespective of the oral dosing paradigm, with a total steady-state plasma concentration achieving 50% of the maximal response (Cave50) of ~100 nM.","Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218541/),nM,100,76960,DB08895,Tofacitinib
,24218541,potency (ED50),"Tofacitinib potency (ED50) in clinical studies was ~3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ~40 nM, derived using Disease Activity Scores from patients with RA.","Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218541/),mg,3.5,76961,DB08895,Tofacitinib
,24218541,total Cave50,"Tofacitinib potency (ED50) in clinical studies was ~3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ~40 nM, derived using Disease Activity Scores from patients with RA.","Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24218541/),nM,40,76962,DB08895,Tofacitinib
,29856518,CL/F,"The parameter estimates (95%CI) for CL/F, Vd/F, and D in a typical individual (white, male, 86 kg, 46 years, CrCl 121 mL/min, PASI 19.8, and CRP 0.267 mg/dL) were 26.7 (25.9, 27.5) L/h, 125 (120.8, 128.3) liters, and 0.69 (0.646, 0.735) hours, respectively.",Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856518/),[l] / [h],26.7,101519,DB08895,Tofacitinib
,29856518,D,"The parameter estimates (95%CI) for CL/F, Vd/F, and D in a typical individual (white, male, 86 kg, 46 years, CrCl 121 mL/min, PASI 19.8, and CRP 0.267 mg/dL) were 26.7 (25.9, 27.5) L/h, 125 (120.8, 128.3) liters, and 0.69 (0.646, 0.735) hours, respectively.",Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856518/),h,0.69,101520,DB08895,Tofacitinib
,27137149,time to peak concentration,"Mean concentration-time profiles for days 1 and 6 were similar, with median time to peak concentration of 0.5 hours on both days.",Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137149/),h,0.5,105128,DB08895,Tofacitinib
,27137149,terminal half-life,"Plasma concentrations declined rapidly following attainment of peak concentrations, with a mean terminal half-life of 3.3 hours on day 1 (single dose) and 2.5 hours on day 6 (multiple dose).",Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137149/),h,3.3,105129,DB08895,Tofacitinib
,27137149,terminal half-life,"Plasma concentrations declined rapidly following attainment of peak concentrations, with a mean terminal half-life of 3.3 hours on day 1 (single dose) and 2.5 hours on day 6 (multiple dose).",Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137149/),h,2.5,105130,DB08895,Tofacitinib
,27137149,accumulation ratio,No accumulation in plasma occurred with twice-daily administration: accumulation ratio of 1.04.,Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27137149/),,1.04,105131,DB08895,Tofacitinib
,25622797,flow rate,The chromatographic analysis was performed on a Waters Alliance system using a gradient mobile phase conditions at a flow rate of 1.0 mL/min and C18 column maintained at 40 ± 1 °C.,Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622797/),[ml] / [min],1.0,119281,DB08895,Tofacitinib
,25622797,total run time,"Tofacitinib and IS eluted at 6.5 and 8.3 min, respectively and the total run time was 10 min.",Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25622797/),min,10,119282,DB08895,Tofacitinib
,31998982,flow rate,"Filgotinib and the IS were extracted from rat plasma using ethyl acetate as an extraction solvent and chromatographed using an isocratic mobile phase (0.2% formic acid:acetonitrile; 20:80, v/v) at a flow rate of 0.9 mL/min on a Gemini C18 column.","Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31998982/),[ml] / [min],0.9,123014,DB08895,Tofacitinib
,31998982,m/z,"The MS/MS ion transitions monitored were m/z 426.3 → 291.3 and m/z 313.2 → 149.2 for filgotinib and the IS, respectively.","Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31998982/),,426.3,123015,DB08895,Tofacitinib
,31998982,m/z,"The MS/MS ion transitions monitored were m/z 426.3 → 291.3 and m/z 313.2 → 149.2 for filgotinib and the IS, respectively.","Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31998982/),,291.3,123016,DB08895,Tofacitinib
,31998982,m/z,"The MS/MS ion transitions monitored were m/z 426.3 → 291.3 and m/z 313.2 → 149.2 for filgotinib and the IS, respectively.","Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31998982/),,313.2,123017,DB08895,Tofacitinib
,31998982,m/z,"The MS/MS ion transitions monitored were m/z 426.3 → 291.3 and m/z 313.2 → 149.2 for filgotinib and the IS, respectively.","Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma, and its application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31998982/),,149.2,123018,DB08895,Tofacitinib
,31319908,CL/F,"The estimates (95% confidence interval) of PK model parameters of a reference patient were CL/F: 20.4 (18.6, 21.8) L/h; V/F: 110 (108, 113) L; and Ka: 13.8 (12.1, 16.6)/h.",Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31319908/),[l] / [h],20.4,129065,DB08895,Tofacitinib
,31319908,V/F,"The estimates (95% confidence interval) of PK model parameters of a reference patient were CL/F: 20.4 (18.6, 21.8) L/h; V/F: 110 (108, 113) L; and Ka: 13.8 (12.1, 16.6)/h.",Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31319908/),l,110,129066,DB08895,Tofacitinib
,31319908,Ka,"The estimates (95% confidence interval) of PK model parameters of a reference patient were CL/F: 20.4 (18.6, 21.8) L/h; V/F: 110 (108, 113) L; and Ka: 13.8 (12.1, 16.6)/h.",Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis . ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31319908/),1/[h],13.8,129067,DB08895,Tofacitinib
,33062629,maximum concentration (Cmax),"The mean maximum concentration (Cmax) and area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for the test formulation were 52.67 ng/mL and 133.86 ng∙h/mL, respectively, and 50.61 ng/mL and 133.49 h∙ng/mL for the reference formulation, respectively.",Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33062629/),[ng] / [ml],52.67,159144,DB08895,Tofacitinib
,33062629,maximum concentration (Cmax),"The mean maximum concentration (Cmax) and area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for the test formulation were 52.67 ng/mL and 133.86 ng∙h/mL, respectively, and 50.61 ng/mL and 133.49 h∙ng/mL for the reference formulation, respectively.",Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33062629/),[ng] / [ml],50.61,159145,DB08895,Tofacitinib
,33062629,area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast),"The mean maximum concentration (Cmax) and area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for the test formulation were 52.67 ng/mL and 133.86 ng∙h/mL, respectively, and 50.61 ng/mL and 133.49 h∙ng/mL for the reference formulation, respectively.",Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33062629/),[ng∙h] / [ml],133.86,159146,DB08895,Tofacitinib
,33062629,area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast),"The mean maximum concentration (Cmax) and area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for the test formulation were 52.67 ng/mL and 133.86 ng∙h/mL, respectively, and 50.61 ng/mL and 133.49 h∙ng/mL for the reference formulation, respectively.",Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33062629/),[h∙ng] / [ml],133.49,159147,DB08895,Tofacitinib
,29282090,AUC at steady state (AUCtau),"Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively.","Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282090/),[h·ng] / [ml],156.6,166783,DB08895,Tofacitinib
,29282090,AUC at steady state (AUCtau),"Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively.","Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282090/),[h·ng] / [ml],118.8,166784,DB08895,Tofacitinib
,29282090,AUC at steady state (AUCtau),"Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively.","Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282090/),[h·ng] / [ml],142.5,166785,DB08895,Tofacitinib
,29282090,Cmax,"Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively.","Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282090/),[ng] / [ml],47.0,166786,DB08895,Tofacitinib
,29282090,Cmax,"Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively.","Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282090/),[ng] / [ml],41.7,166787,DB08895,Tofacitinib
,29282090,Cmax,"Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively.","Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29282090/),[ng] / [ml],66.2,166788,DB08895,Tofacitinib
,32209733,bioavailability,"This might be due to decreased absorption caused by the higher expression of P-glycoprotein and the faster intestinal metabolism caused by the higher expression of intestinal CYP3A1(23), which resulted in the decreased bioavailability of tofacitinib (33.0%) in rats with streptozotocin-induced diabetes mellitus.","Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32209733/),%,33.0,199568,DB08895,Tofacitinib
,30520053,m/,"The precursor/product ion transitions were monitored at m/z 313.3/149.2 and 317.4/149.2 for tofacitinib and tofacitinib-13C3 15 N, respectively, in the positive electrospray ionization mode.",Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520053/),,313.3,213546,DB08895,Tofacitinib
,30520053,m/,"The precursor/product ion transitions were monitored at m/z 313.3/149.2 and 317.4/149.2 for tofacitinib and tofacitinib-13C3 15 N, respectively, in the positive electrospray ionization mode.",Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520053/),,149.2,213547,DB08895,Tofacitinib
,30520053,m/,"The precursor/product ion transitions were monitored at m/z 313.3/149.2 and 317.4/149.2 for tofacitinib and tofacitinib-13C3 15 N, respectively, in the positive electrospray ionization mode.",Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520053/),,317.4,213548,DB08895,Tofacitinib
,30520053,m/,"The precursor/product ion transitions were monitored at m/z 313.3/149.2 and 317.4/149.2 for tofacitinib and tofacitinib-13C3 15 N, respectively, in the positive electrospray ionization mode.",Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520053/),,149.2,213549,DB08895,Tofacitinib
,30520053,extraction recovery,The mean extraction recovery of tofacitinib across quality controls was 98.6%.,Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30520053/),%,98.6,213550,DB08895,Tofacitinib
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],63,225694,DB08895,Tofacitinib
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],59,225695,DB08895,Tofacitinib
,32202190,AUC0-24,"The AUC0-24 of tofacitinib was increased from 1222.81 ± 222.07 to 2016.27 ± 481.62 ng/mL/h, and the difference was significant (p < 0.05).",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[ng] / [h·ml],1222.81,227341,DB08895,Tofacitinib
,32202190,AUC0-24,"The AUC0-24 of tofacitinib was increased from 1222.81 ± 222.07 to 2016.27 ± 481.62 ng/mL/h, and the difference was significant (p < 0.05).",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[ng] / [h·ml],2016.27,227342,DB08895,Tofacitinib
,32202190,Tmax,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,0.75,227343,DB08895,Tofacitinib
,32202190,Tmax,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,3.00,227344,DB08895,Tofacitinib
,32202190,MRT(0-24),"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,4.90,227345,DB08895,Tofacitinib
,32202190,MRT(0-24),"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),h,6.57,227346,DB08895,Tofacitinib
,32202190,clearance,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[l] / [h·kg],4.10,227347,DB08895,Tofacitinib
,32202190,clearance,"Compared with the control group, the Tmax was increased from 0.75 ± 0.29 to 3.00 ± 0.00 h (p < 0.05), and the MRT(0-24) was increased from 4.90 ± 0.51 to 6.57 ± 0.66 h (p < 0.05), but the clearance was obviously decreased from 4.10 ± 0.72 to 2.42 ± 0.70 L/h/kg (p < 0.05) in experimental group.",Effects of naringenin on the pharmacokinetics of tofacitinib in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32202190/),[l] / [h·kg],2.42,227348,DB08895,Tofacitinib
,25298296,total run time,"After a solid-phase extraction procedure, the separation of the analytes and IS was performed on a Chromolith RP₁₈e column using an isocratic mobile phase of 5 m m ammonium acetate (pH 5.0) and acetonitrile at a ratio of 25:75 (v/v) using flow-gradient with a total run time of 3.5 min.",A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25298296/),min,3.5,232174,DB08895,Tofacitinib
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,13.8,233249,DB08895,Tofacitinib
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,13.3,233250,DB08895,Tofacitinib
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,25.9,233251,DB08895,Tofacitinib
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,25.4,233252,DB08895,Tofacitinib
,32289835,flow-rate,"The chromatographic analysis was performed using an isocratic mobile phase comprising 10 mM ammonium acetate (pH 4.5) and acetonitrile (70:30, v/v) at a flow-rate of 0.8 mL/min on a Hypersil Gold C18 column.","Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32289835/),[ml] / [min],0.8,233981,DB08895,Tofacitinib
,32289835,total run time,"Filgotinib and the IS eluted at 5.56 and 4.28 min, respectively with a total run time of 10 min.","Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32289835/),min,10,233982,DB08895,Tofacitinib
,24030917,AUC(0-∞) ratios,"Relative to patients with normal renal function, mean (90% CI) AUC(0-∞) ratios were 137% (97-195), 143% (101-202), and 223% (157-316) in patients with mild, moderate, and severe renal impairment, respectively.","Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24030917/),%,137,240651,DB08895,Tofacitinib
,24030917,AUC(0-∞) ratios,"Relative to patients with normal renal function, mean (90% CI) AUC(0-∞) ratios were 137% (97-195), 143% (101-202), and 223% (157-316) in patients with mild, moderate, and severe renal impairment, respectively.","Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24030917/),%,143,240652,DB08895,Tofacitinib
,24030917,AUC(0-∞) ratios,"Relative to patients with normal renal function, mean (90% CI) AUC(0-∞) ratios were 137% (97-195), 143% (101-202), and 223% (157-316) in patients with mild, moderate, and severe renal impairment, respectively.","Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24030917/),%,223,240653,DB08895,Tofacitinib
,29145097,flow rate,"Baseline chromatographic resolution of defactinib and the I.S. was achieved on an Atlantis dC18 column using an isocratic mobile phase comprising 0.2% formic acid in water and acetonitrile (25:75, v/v) delivered at a flow rate of 0.5mL/min.","LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29145097/),[ml] / [min],0.5,241632,DB08895,Tofacitinib
,29145097,total chromatographic run time,The total chromatographic run time was 2.50min.,"LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29145097/),min,2.50,241633,DB08895,Tofacitinib
,30108938,IC50,Compound (R)-6c exhibited an IC50 value of 8.5 nM against JAK1 with a selectivity index of 48 over JAK2.,"Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30108938/),nM,8.5,244273,DB08895,Tofacitinib
,30108938,selectivity index,Compound (R)-6c exhibited an IC50 value of 8.5 nM against JAK1 with a selectivity index of 48 over JAK2.,"Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30108938/),,48,244274,DB08895,Tofacitinib
,34008179,half-life,Oral tofacitinib undergoes extensive hepatic metabolism and has numerous drug interactions and a half-life of 3 hours necessitating twice daily dosing.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),h,3,250883,DB08895,Tofacitinib
,34008179,Total treatment response,Total treatment response to tofacitinib was 37.5%.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),%,37.5,250884,DB08895,Tofacitinib
,34008179,maximum plasma concentration,Mean maximum plasma concentration was 43.18 ng/ml occurring after 1 hour.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),[ng] / [ml],43.18,250885,DB08895,Tofacitinib
up to,34008179,Elimination half-life,Elimination half-life is estimated to be up to 11 hours.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),h,11,250886,DB08895,Tofacitinib
up to,34008179,half-life,"An estimated half-life of up to 11 hours may be achieved with sublingual tofacitinib, which is significantly longer than the oral form and may facilitate daily dosing.",Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),h,11,250887,DB08895,Tofacitinib
,26970526,time to maximum plasma concentration,"In study A (N = 24), the XR and IR formulations achieved time to maximum plasma concentration at 4 hours and 0.5 hours postdose, respectively; terminal half-life was 5.9 hours and 3.2 hours, respectively.",Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970526/),h,4,273274,DB08895,Tofacitinib
,26970526,time to maximum plasma concentration,"In study A (N = 24), the XR and IR formulations achieved time to maximum plasma concentration at 4 hours and 0.5 hours postdose, respectively; terminal half-life was 5.9 hours and 3.2 hours, respectively.",Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970526/),h,0.5,273275,DB08895,Tofacitinib
,26970526,terminal half-life,"In study A (N = 24), the XR and IR formulations achieved time to maximum plasma concentration at 4 hours and 0.5 hours postdose, respectively; terminal half-life was 5.9 hours and 3.2 hours, respectively.",Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970526/),h,5.9,273276,DB08895,Tofacitinib
,26970526,terminal half-life,"In study A (N = 24), the XR and IR formulations achieved time to maximum plasma concentration at 4 hours and 0.5 hours postdose, respectively; terminal half-life was 5.9 hours and 3.2 hours, respectively.",Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970526/),h,3.2,273277,DB08895,Tofacitinib
